Hypogonadism and Mortality in Aged Hospitalized Male Patients: A 5-Year Prospective Observational Study

Abstract

Objective: To investigate the relationship between hypogonadism and mortality in aged hospitalized male patients.

Design: A 5-year prospective observational study was conducted. Gonadal function was assessed at hospital admission and mortality was registered in the follow-up period.

Patients and Methods: We studied all patients≥65 years admitted for any reason during 2010 and 2011. Serum T concentrations were quantified in all patients. Hypogonadism was defined by the presence of serum T levels<200 ng/dl. Number of deaths and all-cause and cardiovascular (CV) mortality were registered until December 31^st, 2014.

Results: During the study 150 patients were admitted and 103 (68.7%) of them died during follow-up. Hypogonadism was positively associated with mortality (P=0.036). The percentage of hypogonadal patients was significantly (P=0.02) higher in the group of patients who died in hospital compared with those who died after hospital discharge and those who survived. CV disease was the main cause of death in 52 patients (50.5%). Kaplan-Meier analysis showed a median survival time for all-cause mortality of 2.0 (0–16.5) months and 21.0 (5.0–33.2) months for patients with and without hypogonadism, respectively (P<0.001). Similar findings were found when analyzing mortality due to CV disease (P=0.009). Hypogonadism was a strong independent predictor for all-cause (adjusted multivariate analysis, HR 3.35; 1.55–7.23, P=0.002) and CV mortality (HR 2.14; 1.18–3.86, P=0.012).

Conclusions: Hypogonadism discovered during hospitalization is associated with in-hospital and long-term mortality in elderly male patients and predicts both all-cause mortality and CV mortality in this population.

Key words

morbidity - mortality - elderly - testosterone - gonadotropins - hypogonadism

• References

• 1 Wang C, Nieschlag E, Swerdloff R et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008; 159: 507-514
• 2 Venkat K, Desai M, Arora MM et al. Age-related changes in sex steroid levels influence bone mineral density in healthy indian men. Osteoporos Int 2009; 20: 955-962
• 3 Saad F, Gooren LJ. Late onset hypogonadism of men is not equivalent to the menopause. Maturitas 2014; 79: 52-57
• 4 Araujo AB, Esche GR, Kupelian V et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92: 4241-4247
• 5 Wang C, Nieschlag E, Swerdloff R et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009; 30: 1-9
• 6 Tajar A, Huhtaniemi IT, O’Neill TW et al. Characteristics of androgen deficiency in late-onset hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012; 97: 1508-1516
• 7 Cauley JA, Ewing SK, Taylor BC et al. Sex steroid hormones in older men: Longitudinal associations with 4.5-year change in hip bone mineral density – the osteoporotic fractures in men study. J Clin Endocrinol Metab 2010; 95: 4314-4323
• 8 Camacho EM, Huhtaniemi IT, O'Neill TW et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: Longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013; 168: 445-455
• 9 Araujo AB, Dixon JM, Suarez EA et al. Clinical review: Endogenous testosterone and mortality in men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 3007-3019
• 10 Pye SR, Huhtaniemi IT, Finn JD et al. Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metab 2014; 99: 1357-1366
• 11 Iglesias P, Prado F, Macias MC et al. Hypogonadism in aged hospitalized male patients: Prevalence and clinical outcome. J Endocrinol Invest 2014; 37: 135-141
• 12 Iglesias P, Prado F, Munoz A et al. Natural course of hypogonadism diagnosed during hospitalization in aged male patients. Endocrine 2015; 48: 978-984
• 13 Harman SM, Metter EJ, Tobin JD et al. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-731
• 14 Vermeulen A, Kaufman JM. Diagnosis of hypogonadism in the aging male. Aging Male 2002; 5: 170-176
• 15 Araujo AB, O’Donnell AB, Brambilla DJ et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89: 5920-5926
• 16 Yeap BB, Hyde Z, Almeida OP et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 2009; 94: 2353-2359
• 17 Hyde Z, Norman PE, Flicker L et al. Elevated LH predicts ischaemic heart disease events in older men: The Health in Men Study. Eur J Endocrinol 2011; 164: 569-577
• 18 Rastrelli G, Corona G, Lotti F et al Relationship of testis size and LH levels with incidence of major adverse cardiovascular events in older men with sexual dysfunction. J Sex Med 2013; 10: 2761-2773
• 19 Haring R, Teng Z, Xanthakis V et al RS. Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study. Clin Endocrinol (Oxf) 2013; 78: 629-634
• 20 Khaw KT, Dowsett M, Folkerd E et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-norfolk) Prospective Population Study. Circulation 2007; 116: 2694-2701
• 21 Haring R, Volzke H, Steveling A et al Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur Heart J 2010; 31: 1494-1501
• 22 Smith GD, Ben-Shlomo Y, Beswick A et al. Cortisol, testosterone, and coronary heart disease: Prospective evidence from the Caerphilly study. Circulation 2005; 112: 332-340
• 23 Araujo AB, Kupelian V, Page ST et al. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 2007; 167: 252-1260
• 24 Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75
• 25 Tivesten A, Vandenput L, Labrie F et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 2009; 94: 2482-2488
• 26 Haring R, Teng Z, Xanthakis V et al Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study. Clin Endocrinol (Oxf) 2013; 78: 629-634
• 27 Hyde Z, Norman PE, Flicker L et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: The Health in Men Study. J Clin Endocrinol Metab 2012; 97: 179-189